HealthEquity, Inc.

HealthEquity, Inc.

HQYNYSE / NASDAQHealthcareSmall cap

$94.75-$2.63 (-2.7%)

Last close · Data as of Nov 20, 2026

Market cap
$7.2B
P/E
33.4x
EV / EBITDA
16.1x
Revenue
$1.3B
Net margin
16.4%
ROCE
10.2%

-5.9% over the last year

HealthEquity, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-1.9%
3M
-9.1%
6M
+8.2%
1Y
-5.9%
5Y
+54.5%

52-week range

Day change -$2.63 (-2.7%) from $97 to $95 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in HQY, bought on each weekday since 2021.

News & filings

What HealthEquity filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthEBITDA grew 44.3% in fiscal 2026, 34.8 points more than revenue.

Concerns

No concern stands out for this company on the data on file.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2026

Rule-based from financial data. Not advice.

About the company

HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. It offers health savings accounts (HAS); investment platform; online-only automated investment advisory services through Advisor, a Web-based tool.

Read moreShow less

HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. It offers health savings accounts (HAS); investment platform; online-only automated investment advisory services through Advisor, a Web-based tool. The company also provides flexible spending accounts (FSA) for health and dependent care; health reimbursement arrangements; and Consolidated Omnibus Budget Reconciliation Act continuation services, as well as administers pre-tax commuter benefit programs. In addition, the company offers HSA and FSA members with access to certain healthcare products, programs, and services through its marketplace. It serves clients through a direct sales force; and brokers and advisors, a network of health plans, benefits administrators, benefits brokers and consultants, and retirement plan record-keepers. HealthEquity, Inc. was incorporated in 2002 and is based in Draper, Utah.

Sector
Healthcare
Shares outstanding
86.1M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$7.2B
P/E
33.4x
P/B
3.4x
EV / EBITDA
16.1x
EV / Sales
6.0x
P/S
5.5x
52-week high
$108.84
52-week low
$73.21

Profitability

Operating margin
24.9%
Net margin
16.4%
EBITDA margin
37.2%
ROE
10.2%
ROCE
10.2%
ROIC
9.3%
ROA
6.4%
Asset turnover
0.39

Growth

Revenue
$1.3B
Revenue growth, 1Y
9.5%
Revenue CAGR, 3Y
15.1%
Net profit growth, 1Y
122.5%
Free cash flow
$408.3M

Solvency

Current ratio
3.27
Debt / Equity
0.48
Debt / Assets
0.30
CFO / Net profit
2.12
Cash / Market cap
4.4%

Where the revenue went

Of every $100 of FY2026 revenue, $16 was left as net income.

HealthEquity, Inc. income statement flow, FY2026
HealthEquity, Inc. income statement flow, FY2026: flows
FromToAmount
RevenueCost of revenue$400.3M
RevenueGross profit$913.1M
Gross profitResearch and development$262.5M
Gross profitSelling, general and administrative$215.2M
Gross profitOther operating expenses$108.0M
Gross profitOperating income$327.5M
Operating incomePretax income$277.4M
Operating incomeInterest and other expense$50.1M
Pretax incomeTax and other$62.2M
Pretax incomeNet income$215.2M

Revenue and net profit

Revenue grew 9.5% in FY2026; net profit is the dashed line.

HealthEquity, Inc. revenue and net profit by fiscal year
HealthEquity, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2023$861.7M-$26.1M
FY2024$999.6M$55.7M
FY2025$1.2B$96.7M
FY2026$1.3B$215.2M

Cash flows

FY2026: $457.1M from operations, $408.3M free after investment (dashed).

HealthEquity, Inc. operating and free cash flow by fiscal year
HealthEquity, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2023$150.7M$31.5M
FY2024$242.8M$196.8M
FY2025$339.9M-$165.6M
FY2026$457.1M$408.3M

Growth

Latest fiscal year 2026: each figure with its change over the year before.

Revenue
$1.3B+9.5%1Y
EBITDA
$489.2M+44.3%1Y
Net profit
$215.2M+122.5%1Y
Cash from operations
$457.1M+34.5%1Y
Free cash flow
$408.3M
Revenue CAGR, 3Y
15.1%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2026$1.3B$489.2M$215.2M$408.3M10.2%+9.5%+122.5%

Monthly returns

Month-by-month returns of HQY across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2026.

LineFY2026
Assets$3.4B
Liabilities$1.3B
Equity$2.1B
Paid-in capital$1.9B
Retained earnings$195.9M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; HQY highlighted.

P/E against peers

HQY trades at 33.4x earnings against a peer median of -21.7x.

  1. HealthEquity, Inc. (this company)33.4x

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): Nuvalent, Inc., Praxis Precision Medicines, Inc., Vaxcyte, Inc., Apogee Therapeutics, Inc., Spyre Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
HealthEquity, Inc.HQYthis company$7.2B33.4x3.4x10.2%16.1x
ImmunityBio, Inc.IBRX$7.6B-21.7x-15.3x70.2%-36.1x
Nuvalent, Inc.NUVL$7.4B-17.5x5.9x-34.1%—
Praxis Precision Medicines, Inc.PRAX$7.4B-24.3x8.4x-34.5%-21.5x
Oscar Health, Inc.OSCR$7.1B-16.1x7.3x-45.3%—
Vaxcyte, Inc.PCVX$7.0B-9.2x2.6x-28.5%-7.8x
Apogee Therapeutics, Inc.APGE$6.9B-26.8x7.6x-28.3%-23.7x
Spyre Therapeutics, Inc.SYRE$6.8B—9.5x-21.7%—
Arcellx, Inc.ACLX$6.7B-29.4x16.7x-56.9%-30.2x
Peer median—-21.7x7.4x-31.3%-23.7x

Year-to-date ROI

HQY since 1 January, against earlier years.

Historical volatility

HQY's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

HealthEquity, Inc. operating margin by fiscal year
HealthEquity, Inc. operating margin by fiscal year
DateOperating margin
FY20234.4%
FY202412.8%
FY202516.9%
FY202624.9%
LineFY2026
Cost of revenueCost Of Revenue$400.3M
Gross profitGross Profit$913.1M
Operating expensesOperating Expense$585.6M
Research and developmentResearch And Development$262.5M
Depreciation and amortisationDepreciation And Amortization In Income Statement$108.0M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$108.0M
Amortization$108.0M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$108.0M
Total expensesTotal Expenses$986.0M
Pretax incomePretax Income$277.4M

Learn while you research

Academy chapters picked for HealthEquity, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 33.4, learn when high multiples are justified.6 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →